Related references
Note: Only part of the references are listed.Comrad: detection of expressed rearrangements by integrated analysis of RNA-Seq and low coverage genome sequence data
Andrew McPherson et al.
BIOINFORMATICS (2011)
ChimeraScan: a tool for identifying chimeric transcription in sequencing data
Matthew K. Iyer et al.
BIOINFORMATICS (2011)
Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
Brett S. Carver et al.
CANCER CELL (2011)
Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer
J. Chad Brenner et al.
CANCER CELL (2011)
New Strategies in Metastatic Melanoma: Oncogene-Defined Taxonomy Leads to Therapeutic Advances
Keith T. Flaherty et al.
CLINICAL CANCER RESEARCH (2011)
Use of Whole-Genome Sequencing to Diagnose a Cryptic Fusion Oncogene
John S. Welch et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Multiplex Mutation Screening by Mass Spectrometry Evaluation of 820 Cases from a Personalized Cancer Medicine Registry
Carol Beadling et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2011)
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
Wendy De Roock et al.
LANCET ONCOLOGY (2011)
Initial genome sequencing and analysis of multiple myeloma
Michael A. Chapman et al.
NATURE (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
Xose S. Puente et al.
NATURE (2011)
Early Accelerated Approval for Highly Targeted Cancer Drugs
Bruce A. Chabner
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Simon A. Forbes et al.
NUCLEIC ACIDS RESEARCH (2011)
High Throughput Interrogation of Somatic Mutations in High Grade Serous Cancer of the Ovary
Ursula A. Matulonis et al.
PLOS ONE (2011)
A MEK Inhibitor Abrogates Myeloproliferative Disease in Kras Mutant Mice
Natalya Lyubynska et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value
Brian A. Walker et al.
BLOOD (2010)
BRAF, a Target in Melanoma Implications for Solid Tumor Drug Development
Keith T. Flaherty et al.
CANCER (2010)
An Oncogenic Role for ETV1 in Melanoma
Judit Jane-Valbuena et al.
CANCER RESEARCH (2010)
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
Dora Dias-Santagata et al.
EMBO MOLECULAR MEDICINE (2010)
Do We Have to Change the Way Targeted Drugs Are Developed?
Alberto Ocana et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers
Daniel D. Von Hoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
International network of cancer genome projects
Thomas J. Hudson et al.
NATURE (2010)
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma
Nallasivam Palanisamy et al.
NATURE MEDICINE (2010)
Advances in understanding cancer genomes through second-generation sequencing
Matthew Meyerson et al.
NATURE REVIEWS GENETICS (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing
Rebecca J. Leary et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
PTEN and the PI3-Kinase Pathway in Cancer
Nader Chalhoub et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2009)
Revving the Throttle on an Oncogene: CDK8 Takes the Driver Seat
Ron Firestein et al.
CANCER RESEARCH (2009)
KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer
Jen Jen Yeh et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Complex landscapes of somatic rearrangement in human breast cancer genomes
Philip J. Stephens et al.
NATURE (2009)
Targeted capture and massively parallel sequencing of 12 human exomes
Sarah B. Ng et al.
NATURE (2009)
The Human Gene Mutation Database: 2008 update
Peter D. Stenson et al.
GENOME MEDICINE (2009)
Cell cycle, CDKs and cancer: a changing paradigm
Marcos Malumbres et al.
NATURE REVIEWS CANCER (2009)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
Unregulated smooth-muscle myosin in human intestinal neoplasia
Pia Alhopuro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer
SA Tomlins et al.
SCIENCE (2005)
Tyrosine kinases as targets for cancer therapy
DS Krause et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
BRAF mutation in papillary thyroid carcinoma
J Cohen et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
The protein kinase complement of the human genome
G Manning et al.
SCIENCE (2002)
Share Paper
